EFDID: 567437EFD: View Filing

Issuer: TNF Pharmaceuticals, Inc. (0001321834) - D

Accession: 0001641172-25-026761 (XMLRaw Data) (EDGAREDGAR Files) (Form DForm D)

EDGAR: Issuer Information
  • CIK:
    0001321834
  • Entity Name:
    TNF Pharmaceuticals, Inc.
  • Entity Type:
    Corporation
  • Jurisdiction:
    DELAWARE
  • Year of Inc:
    Within 5 years (2023)
  • Address:
    1185 AVENUE OF THE AMERICAS
    SUITE 249
    NEW YORK, NY 10036
  • Persons:
    Related Persons 7
    Ian Rhodes
    Executive Officer 
    Chief Financial Officer
    Christopher Schreiber
    Director
    Joshua Silverman
    Executive Officer, Director 
    Executive Chairman
    Bruce Bernstein
    Director
    Bill J. White
    Director
    Stephen Friscia
    Director
    Mitchell Glass
    Executive Officer, Director 
    Chief Medical Officer
EDGAR: Offering Information
  • Accession Date:
    09/05/2025
  • First Sale Date:
    09/02/2025
  • Offering Amount:
    $7,000,000
  • Amount Sold:
    $7,000,000
  • Exemptions:
    Rule 506
  • Security Type(s):
    Equity
EFD: Current State Notices

No State Notices found in EFD

EDGAR: Sales Compensation Recipient Information
RecipientCRDBroker DealerBD CRDStates
GP Nurmenkari Inc. 000153480 None None CT, NY
Rodman & Renshaw, LLC 000281264 None None NY
H.C. Wainwright & Co., LLC 000000375 None None NY
EDGAR: Signatures
IssuerSignatureSigner NameTitleSignatureDate
TNF Pharmaceuticals, Inc./s/ Mitchell GlassMitchell GlassChief Medical Officer2025-09-05